BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

701 related articles for article (PubMed ID: 25382750)

  • 21. Abrogation of Gli3 expression suppresses the growth of colon cancer cells via activation of p53.
    Kang HN; Oh SC; Kim JS; Yoo YA
    Exp Cell Res; 2012 Mar; 318(5):539-49. PubMed ID: 22227409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Runt-related transcription factor RUNX3 is a target of MDM2-mediated ubiquitination.
    Chi XZ; Kim J; Lee YH; Lee JW; Lee KS; Wee H; Kim WJ; Park WY; Oh BC; Stein GS; Ito Y; van Wijnen AJ; Bae SC
    Cancer Res; 2009 Oct; 69(20):8111-9. PubMed ID: 19808967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified.
    Mayo LD; Seo YR; Jackson MW; Smith ML; Rivera Guzman J; Korgaonkar CK; Donner DB
    J Biol Chem; 2005 Jul; 280(28):25953-9. PubMed ID: 15843377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dissecting the p53-Mdm2 feedback loop in vivo: uncoupling the role in p53 stability and activity.
    Pant V; Lozano G
    Oncotarget; 2014 Mar; 5(5):1149-56. PubMed ID: 24658419
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TRIM59 is up-regulated in gastric tumors, promoting ubiquitination and degradation of p53.
    Zhou Z; Ji Z; Wang Y; Li J; Cao H; Zhu HH; Gao WQ
    Gastroenterology; 2014 Nov; 147(5):1043-54. PubMed ID: 25046164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The regulation of MDM2 by multisite phosphorylation--opportunities for molecular-based intervention to target tumours?
    Meek DW; Hupp TR
    Semin Cancer Biol; 2010 Feb; 20(1):19-28. PubMed ID: 19897041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HBP1-mediated Regulation of p21 Protein through the Mdm2/p53 and TCF4/EZH2 Pathways and Its Impact on Cell Senescence and Tumorigenesis.
    Chen Y; Pan K; Wang P; Cao Z; Wang W; Wang S; Hu N; Xue J; Li H; Jiang W; Li G; Zhang X
    J Biol Chem; 2016 Jun; 291(24):12688-12705. PubMed ID: 27129219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TAp73 promotes cell survival upon genotoxic stress by inhibiting p53 activity.
    Chen D; Ming L; Zou F; Peng Y; Van Houten B; Yu J; Zhang L
    Oncotarget; 2014 Sep; 5(18):8107-22. PubMed ID: 25237903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo.
    Midgley CA; Desterro JM; Saville MK; Howard S; Sparks A; Hay RT; Lane DP
    Oncogene; 2000 May; 19(19):2312-23. PubMed ID: 10822382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamics in the p53-Mdm2 ubiquitination pathway.
    Brooks CL; Gu W
    Cell Cycle; 2004 Jul; 3(7):895-9. PubMed ID: 15254415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RFWD3-Mdm2 ubiquitin ligase complex positively regulates p53 stability in response to DNA damage.
    Fu X; Yucer N; Liu S; Li M; Yi P; Mu JJ; Yang T; Chu J; Jung SY; O'Malley BW; Gu W; Qin J; Wang Y
    Proc Natl Acad Sci U S A; 2010 Mar; 107(10):4579-84. PubMed ID: 20173098
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells.
    Duan W; Gao L; Wu X; Zhang Y; Otterson GA; Villalona-Calero MA
    Exp Cell Res; 2006 Oct; 312(17):3370-8. PubMed ID: 16934800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protocadherin 17 acts as a tumour suppressor inducing tumour cell apoptosis and autophagy, and is frequently methylated in gastric and colorectal cancers.
    Hu X; Sui X; Li L; Huang X; Rong R; Su X; Shi Q; Mo L; Shu X; Kuang Y; Tao Q; He C
    J Pathol; 2013 Jan; 229(1):62-73. PubMed ID: 22926751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disruption of the RP-MDM2-p53 pathway accelerates APC loss-induced colorectal tumorigenesis.
    Liu S; Tackmann NR; Yang J; Zhang Y
    Oncogene; 2017 Mar; 36(10):1374-1383. PubMed ID: 27617574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma.
    Fornari F; Milazzo M; Galassi M; Callegari E; Veronese A; Miyaaki H; Sabbioni S; Mantovani V; Marasco E; Chieco P; Negrini M; Bolondi L; Gramantieri L
    Mol Cancer Res; 2014 Feb; 12(2):203-16. PubMed ID: 24324033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control.
    Li L; Liao J; Ruland J; Mak TW; Cohen SN
    Proc Natl Acad Sci U S A; 2001 Feb; 98(4):1619-24. PubMed ID: 11172000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mdm2-mediated ubiquitylation: p53 and beyond.
    Marine JC; Lozano G
    Cell Death Differ; 2010 Jan; 17(1):93-102. PubMed ID: 19498444
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cooperation of Musashi-2, Numb, MDM2, and P53 in drug resistance and malignant biology of pancreatic cancer.
    Sheng W; Dong M; Chen C; Wang Z; Li Y; Wang K; Li Y; Zhou J
    FASEB J; 2017 Jun; 31(6):2429-2438. PubMed ID: 28223335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
    Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
    Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MDM2 mediates fibroblast activation and renal tubulointerstitial fibrosis via a p53-independent pathway.
    Ye C; Tang H; Zhao Z; Lei CT; You CQ; Zhang J; Gao P; He FF; Chen S; Wang YM; Zhang C; Su H
    Am J Physiol Renal Physiol; 2017 Apr; 312(4):F760-F768. PubMed ID: 28100501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.